EJPMR, 2026, 13(8), 393-400 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

SYNERGISTIC METABOLIC DYSFUNCTION: INVESTIGATING THE INTERPLAY BETWEEN PCOD, INSULIN RESISTANCE, AND NON-ALCOHOLIC FATTY LIVER DISEASE(NAFLD)

[*1]Dr. Alwin Simon, [2]Jerina C. A., [3]Ashini David

[1]Department(s) and Institution(s) Assistant Professor, Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, J.K.K. Nattraja Educational Institutions, Kumarapalayam, Namakkal, Tamil Nadu-638183.
[2]J.K.K. Nattraja College of Pharmacy.
[3]J.K.K. Nattraja College of Pharmacy.

***Corresponding Author: Dr. Alwin Simon**

Department(s) and Institution(s) Assistant Professor, Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, J.K.K. Nattraja Educational Institutions, Kumarapalayam, Namakkal, Tamil Nadu-638183.

DOI: https://doi.org/10.5281/zenodo.21785756

How to cite this Article: [*1]Dr. Alwin Simon, [2]Jerina C. A., [3]Ashini David (2026). Synergistic Metabolic Dysfunction: Investigating The Interplay Between Pcod, Insulin Resistance, And Non-Alcoholic Fatty Liver Disease(Nafld). European Journal of Pharmaceutical and Medical Research, 13(8), 393–400.

Article Received on 05/07/2026 **Article Revised on 25/07/2026** **Article Published on 01/08/2026**

ABSTRACT

Polycystic ovary syndrome (PCOS), insulin resistance (IR), and non-alcoholic fatty liver disease (NAFLD) are highly prevalent metabolic disorders that frequently coexist through interconnected pathophysiological mechanisms. Their bidirectional relationship is driven by shared processes, including hyperinsulinemia, chronic low-grade inflammation, oxidative stress, adipokine dysregulation, mitochondrial dysfunction, and genetic and epigenetic alterations, resulting in a self-perpetuating cycle that accelerates disease progression. This review summarizes current evidence on the molecular and clinical interplay among PCOS, IR, and NAFLD, highlighting overlapping clinical manifestations, diagnostic challenges, and emerging biomarkers. It further examines the influence of environmental and lifestyle factors, including dietary habits, sedentary behaviour, endocrine-disrupting chemicals, and gut microbiota dysbiosis, on metabolic dysfunction. Current management strategies involving lifestyle modification, insulin-sensitizing agents, glucagon-like peptide-1 receptor agonists, and multidisciplinary care are discussed alongside emerging therapeutic approaches targeting epigenetic regulation and the gut microbiome. Despite significant advances, the absence of unified diagnostic criteria and limited longitudinal evidence continue to hinder integrated management. A comprehensive understanding of the synergistic relationship among PCOS, IR, and NAFLD may facilitate earlier diagnosis, improve risk stratification, and support the development of personalized therapeutic strategies. Future research should prioritize integrated clinical models, molecular biomarkers, and artificial intelligence-based precision medicine to improve long-term metabolic and reproductive outcomes.

KEYWORDS: Adipokines, Precision Medicine, Chronic inflammation, Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease(NAFLD).

1. INTRODUCTION

PCOS is a multifaceted endocrine disorder affecting 8–13% of reproductive-age women globally, making it one of the most common causes of infertility raised by hyperandrogenism, chronic anovulation, and polycystic ovarian morphology, PCOS is closely linked to metabolic dysfunctions, particularly insulin resistance (IR).[1] IR underlies various metabolic and systemic disorders, including PCOS and Non-Alcoholic Fatty Liver Disease (NAFLD). It is characterized by diminished responsiveness of tissues to insulin, resulting in hyperinsulinemia. This compensatory state drives glucose intolerance, lipid dysregulation, and chronic inflammation, thereby contributing to the pathophysiology of both PCOS and NAFLD.[5] NAFLD, encompassing a spectrum from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis, is the most common cause of chronic liver disease worldwide. In women with PCOS, NAFLD prevalence is significantly elevated.[2]

1.1 Rationale for Investigating Their Interplay

PCOS, IR, and NAFLD share overlapping pathophysiological pathways that establish a synergistic relationship. Chronic inflammation, dysregulated lipid metabolism, and hormonal imbalances contribute to a vicious cycle, amplifying the severity of each condition.[2][7] NAFLD-associated systemic inflammation exacerbates IR, which in turn worsens PCOS symptoms.[13]

1.2 Aim and Scope of the Review

This review aims to.

Elucidate Shared Mechanisms: Explore the common molecular pathways, including insulin signaling and inflammatory cascades, linking PCOS, IR, and NAFLD.[2]

Examine Clinical and Diagnostic Challenges: Discuss overlapping symptoms and the limitations of current diagnostic tools.[7]

2. METHODOLOGY

2.1 Literature Search Strategy

A comprehensive literature search was conducted to gather relevant studies exploring the interplay between Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), and Non-Alcoholic Fatty Liver Disease (NAFLD). The primary databases utilized for the search included Scopus, PubMed and Web of Science. These databases are widely regarded for their extensive collections of peer-reviewed literature in the fields of medicine, endocrinology, and hepatology, ensuring a robust collection of articles. The search was not limited to a specific date range, but emphasis was placed on articles published between 2000 and 2023 to incorporate the most current findings. Inclusion criteria were studies that discussed the mechanisms, epidemiology, diagnostic tools, or therapeutic approaches related to PCOS, IR, and NAFLD. Exclusion criteria encompassed studies that focused on non-metabolic aspects, podiatric populations, or those lacking clear methodological rigor. Additionally, non-English language articles were excluded due to the limitation in language accessibility.

2.2 Data Synthesis Approach

This review follows a **systematic synthesis approach** to integrate and analyse findings from various studies related to the pathophysiological mechanisms, diagnostic tools, and therapeutic approaches for PCOS, IR, and NAFLD.

2.3 Quality Assessment

To ensure the reliability of the selected studies, a quality assessment was performed based on the **Newcastle-Ottawa Scale (NOS)** for cohort studies and case-control studies.[19] This tool evaluates studies based on selection criteria, comparability, and outcome assessment. Studies with a high risk of bias were excluded from the final synthesis, ensuring that only high-quality data contributed to the conclusions of the review.

3. Pathophysiology

3.1 Mechanism of PCOD and insulin resistance

Hormonal abnormalities, insulin resistance (IR), and metabolic dysfunction are the hallmarks of PCOS, a complicated endocrine condition. Insulin resistance (IR), which is associated with obesity and leads to hyperinsulinemia, is present in a sizable percentage of women with PCOS. By boosting androgen production, this disorder makes ovarian dysfunction worse and causes symptoms including hirsutism and anovulation.[13] Hormonal Imbalances: Elevated levels of luteinizing hormone (LH) and androgens, along with decreased follicle-stimulating hormone (FSH), disrupt normal ovarian function. The excess androgens can lead to the development of ovarian cysts.[13] Inflammation: Chronic low-grade inflammation is common in PCOS and may contribute to IR. Inflammatory markers are often elevated in affected women, linking metabolic dysfunction with reproductive issues.[14]

3.2 Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

The main characteristic of non-alcoholic fatty liver disease (NAFLD) is excessive hepatic fat accumulation without substantial alcohol intake.[4] Several interrelated pathways are involved in its pathogenesis: Insulin Resistance: By encouraging lipolysis in adipose tissue, which raises the liver's levels of free fatty acids (FFAs), IR plays a critical part in the development of NAFLD. Numerous studies have demonstrated that CD36, which promotes intracellular FFA uptake and trafficking, may have a role in the development of NASH in relation to the liver's uptake of FFA.[27] Hepatic steatosis is the outcome of this process' stimulation of de novo lipogenesis (DNL).[14][15] Multiple-Hit Hypothesis: The pathogenesis is often described using the "multiple-hit" theory, where the first hit is hepatic steatosis due to IR, followed by secondary hits such as oxidative stress, mitochondrial dysfunction, and inflammation. These factors can lead to steatohepatitis (NASH) and fibrosis.[14][13] Dietary Factors: High-fat and high-sugar diets, particularly those rich in fructose, exacerbate lipid accumulation in the liver. Fructose metabolism leads to increased lipogenesis and hepatic stress responses that contribute to inflammation and fibrosis.[16][15] Novel loci linked to the disease severity phenotypes of NAFLD and NASH have been found by numerous genome-wide association studies. Although glycerolipid hydrolyzer PNPLA3 (patatin-like phospholipase domain-containing protein 3) is known to be expressed in many different organs, the liver and kidneys have been found to express it at notably high levels. [27] [15]

3.3 The Triangular Interplay

Feedback Loops: The interplay between PCOS, IR, and NAFLD forms a triangular feedback loop. Hyperinsulinemia in PCOS exacerbates hepatic lipid

accumulation, while liver inflammation in NAFLD worsens systemic IR, creating a self-perpetuating cycle. This bidirectional relationship intensifies the severity of both conditions.[4]

Role of Adipokines: Dysregulated adipokines, such as reduced adiponectin and increased leptin, play a central role in linking PCOS and NAFLD. Adiponectin deficiency impairs insulin sensitivity and promotes hepatic inflammation, while elevated leptin levels enhance pro-inflammatory signalling.[26]

Mitochondrial Dysfunction: Impaired mitochondrial biogenesis, prevalent in both PCOS and NAFLD, results in inadequate energy production and heightened oxidative stress. This dysfunction exacerbates systemic inflammation and IR, fueling the pathophysiological connections.[13]

4. Clinical Manifestations and Diagnostic Intersections

4.1 Overlapping Clinical Features

The clinical features of **Polycystic Ovary Syndrome (PCOS)**, **Insulin Resistance (IR)**, and **Non-Alcoholic Fatty Liver Disease (NAFLD)** often overlap, complicating diagnosis and treatment. Common symptoms that occur across these three conditions include.

Fatigue: Many women with PCOS report persistent fatigue, which is also common in those with NAFLD and insulin resistance. This fatigue may stem from metabolic dysregulation, poor sleep quality, or hormonal imbalances, all of which are common in these conditions. Fatigue.[1]

Obesity: Central obesity is a significant risk factor and common feature in both PCOS and insulin resistance, with a strong correlation between visceral fat and the degree of insulin resistance.[3]

Menstrual disturbances such as oligomenorrhea (infrequent menstruation) and amenorrhea (absence of menstruation) are typical in PCOS, linked to hormonal dysfunctions, particularly elevated luteinizing hormone (LH) and androgens.[7]

4.2 Diagnostic Tools and Biomarkers

PCOS: Diagnosis is typically based on the Rotterdam criteria, requiring at least two of the following three features:

1. Oligo- or anovulation: Irregular or absent menstrual cycles.
2. Hyperandrogenism: Clinical signs such as hirsutism and acne, or biochemical evidence of elevated testosterone.
3. Polycystic ovaries: Identified via ultrasound, characterized by more than 12 follicles in each ovary.[3]

Insulin Resistance (IR): Euglycemic-hyperinsulinemic clamp is considered the gold standard for diagnosing IR, but it is rarely used due to its complexity and cost. Instead, HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is widely used.[16] A HOMA-IR value greater than 2.5 typically indicates insulin resistance. Additionally, oral glucose tolerance tests (OGTT) are used to assess insulin sensitivity and detect early stages of IR.

NAFLD: Liver enzymes such as ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are commonly used to assess liver dysfunction. Elevated ALT/AST levels often correlate with liver injury due to NAFLD. Non-invasive imaging techniques, including ultrasound, CT, and MRI, can help visualize hepatic fat accumulation. The FibroScan method is increasingly used to assess liver stiffness, which helps determine liver fibrosis and progression to NASH. While liver biopsy remains the gold standard for diagnosing and not commonly used in routine clinical practice.[3] [6]

4.3 Challenges in Diagnosis

Underdiagnosis due to symptom overlap: The overlapping symptoms across the conditions frequently lead to underdiagnosis, especially in women with subtle or early manifestations. For instance, while many women with PCOS exhibit varying degrees of insulin resistance, they may not show obvious signs of NAFLD until the condition progresses to more advanced stages.[7]

5. Molecular and Genetic Mechanisms

5.1 Adipokines and Cytokines

Adipokines, secreted primarily by adipose tissue, are crucial in the regulation of metabolic homeostasis, including insulin sensitivity. Leptin and adiponectin are two key adipokines with opposing effects on metabolism. **Leptin** is typically elevated in obesity and contributes to **insulin resistance** (IR) by inducing chronic low-grade inflammation. High levels of leptin, often observed in conditions like PCOS, exacerbate insulin resistance by interfering with insulin signaling pathways. **Adiponectin**, on the other hand, is typically reduced in individuals with obesity and insulin resistance.

Low levels of adiponectin are commonly seen in women with PCOS, and studies suggest that this reduced adiponectin is associated with higher systemic inflammation and worsened insulin resistance.[8]

In addition to adipokines, **pro-inflammatory cytokines** such as **TNF-α** and **IL-6** play critical roles in driving systemic inflammation, which further contributes to insulin resistance. Elevated levels of these cytokines are often observed in both PCOS and NAFLD.[6]

5.2 Epigenetic and Genetic Influences

Several **single nucleotide polymorphisms (SNPs)** have been associated with an increased risk of developing metabolic dysfunction in these conditions.[26] In PCOS,

genetic variants in **insulin receptor substrate (IRS)** and **PCOS susceptibility genes** like **THADA** (thyroid adenoma-associated) have been identified as contributing to insulin resistance and ovarian dysfunction.[5] **Epigenetic Modifications:** Beyond genetic predisposition, epigenetic factors such as DNA methylation, histone modification, and non-coding RNA expression are critical in the development and progression of metabolic disorders.[5] In PCOS, DNA methylation patterns in genes involved in insulin signaling have been observed. Epigenetic regulation of **mitochondrial biogenesis** also plays a role in metabolic disorders. Changes in the expression of mitochondrial-related genes can influence the development of both insulin resistance and NAFLD.[5]

5.3 Role of Mitochondrial Dysfunction

Impaired Mitochondrial Biogenesis: In women with PCOS, mitochondrial dysfunction has been linked to altered ovarian function and insulin resistance. Reduced mitochondrial DNA copy numbers and impaired mitochondrial enzyme activity are observed in the ovaries of PCOS patients, contributing to the metabolic and reproductive abnormalities seen in the disorder.[5]

Oxidative Stress: In the liver, this oxidative stress contributes to the progression from simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis[6] Mitochondrial oxidative stress also exacerbates inflammation, a key driver of both insulin resistance and NAFLD.[5]

6. Environmental and Lifestyle Contributions

6.1 Dietary Factors

High-Glycemic Index (GI) Foods: Foods with a high GI, such as refined sugars and processed carbohydrates, lead to rapid spikes in blood glucose and insulin levels. Chronic consumption of high-GI foods exacerbates insulin resistance promoting increased lipogenesis in the liver and visceral fat accumulation. Studies show that diets high in refined sugars and high-GI foods contribute to greater hepatic fat accumulation, worsening NAFLD.[1]

Saturated Fats: Diets rich in saturated fats, found in red meat, full-fat dairy, and fried foods, have been linked to increased insulin resistance and impaired liver function.[1] The Mediterranean diet, characterized by high intake of fruits, vegetables, whole grains, olive oil, and fish, has shown protective effects against insulin resistance and NAFLD. This diet is rich in monounsaturated fats (particularly from olive oil) and omega-3 fatty acids, both of which improve insulin sensitivity and reduce liver fat accumulation. Research supports its role in reducing oxidative stress and inflammation.[7] [16] [20]

Diets low in carbohydrates, particularly those that limit refined grains and simple sugars, can assist increase insulin sensitivity and glycemic management. According to studies, these diets can help people with PCOS and NAFLD drastically lower their liver fat. Low-carb diets improve insulin resistance and lower the risk of metabolic problems by encouraging fat oxidation and lowering the liver's dependency on glucose.[14]

6.2 Sedentary Lifestyles

One of the most potent environmental risk factors for both IR and NAFLD is obesity, especially central or visceral obesity. The buildup of fat around the belly, which is very metabolically active and contributes to a chronic low-grade inflammatory state, is a hallmark of central obesity. Visceral fat, an active endocrine organ, secretes pro-inflammatory cytokines including TNF-α and IL-6, which impede insulin signaling and lead to central obesity and insulin resistance. Hepatic fat buildup and the development of non-alcoholic fatty liver disease (NAFLD) are further encouraged by the excess fat in the abdominal area, which increases lipolysis and releases free fatty acids (FFAs) into the bloodstream.[2] Additionally, central obesity causes adipokine dysregulation, which lowers insulin-sensitive hormones like adiponectin.[26]

Insulin sensitivity and obesity are both made worse by sedentary lifestyles. Regular exercise is crucial for lowering belly fat, enhancing insulin sensitivity, and preserving metabolic health. It has been demonstrated that aerobic exercise increases the oxidation of fat and reduces the amount of liver fat. On the other hand, sedentary lifestyles fuel a vicious cycle of deteriorating IR and metabolic syndrome. Insufficient physical exercise plays a major role in the development of PCOS and NAFLD.[16]

6.3 Environmental Toxins

Endocrine-disrupting chemicals (EDCs) and other toxins interfere with hormone control, which contributes to metabolic dysfunction. These substances, which can be found in personal care items, plastics, and pesticides, have been demonstrated to change endocrine signaling pathways, which can lead to fatty liver disease and insulin resistance.

Bisphenol A (BPA) and Phthalates: phthalates, which are plasticizers used in many household products, and BPA, which is frequently found in plastics, are known to interfere with endocrine function. BPA can disrupt insulin signaling pathways and mimic estrogen, which can lead to the emergence of metabolic diseases. Increased obesity, insulin resistance, and the development of non-alcoholic fatty liver disease have all been linked to BPA and phthalates.[2] Research has indicated that exposure to these substances during crucial developmental periods may result in long-term metabolic effects.[1]

Other Endocrine Disruptors: (Review article (1)) organic pollutants (POPs), such as pesticides and industrial chemicals, are also linked to metabolic

dysfunction. These chemicals accumulate in adipose tissue and can increase inflammation, alter lipid metabolism, and disrupt insulin sensitivity. POPs have been associated with an increased risk of NAFLD, as they interfere with the liver's ability to process fats efficiently, leading to fat buildup in liver cells.[16]

6.4 Gut Microbiota Dysbiosis

A complex ecology of bacteria called the gut microbiota lives in the intestines and is essential to metabolic function. An imbalance in the composition of the gut microbiota, or dysbiosis, is becoming recognized as a key player in the pathophysiology of metabolic diseases, such as IR and NAFLD.

Changed Microbiota Composition in Metabolic Syndrome: Research has indicated that people with metabolic syndrome, which includes PCOS and NAFLD, frequently have changed gut microbiota. A decrease in helpful bacteria and an increase in pro-inflammatory bacteria are the hallmarks of this dysbiosis. This imbalance can exacerbate the metabolic dysfunction associated with insulin resistance and systemic inflammation. The function of the gut microbiota in lipid and carbohydrate metabolism can have a direct effect on insulin sensitivity and liver health.[16]

Microbial Metabolites' Role: During the fermentation of dietary fibers, beneficial gut bacteria produce short-chain fatty acids (tFAs), which are essential for controlling insulin sensitivity and liver function. Butyrate, propionate, and acetate are SCFAs that enhance glucose metabolism and lessen inflammation. Deficiency in SCFAs brought on by dysbiosis can exacerbate insulin resistance and lead to hepatic fat buildup. Research has indicated that SCFAs can enhance hepatic insulin sensitivity and could be a viable therapeutic target for the treatment of IR and NAFLD.[3] [14]

7. Therapeutic and Management Approaches

7.1 Lifestyle Modifications

Dietary Interventions

Foods with a low Glycemic Index (GI): Insulin sensitivity is enhanced and blood glucose levels are stabilized by including low-GI meals such as whole grains, legumes, and non-starchy vegetables. By lowering hepatic fat buildup, low-GI diets can effectively lower hyperglycemia and slow the course of non-alcoholic fatty liver disease.[20]

Omega-3 Supplementation: Fish oil and flaxseeds are good sources of omega-3 fatty acids, which lower inflammation and liver fat. According to clinical research, taking omega-3 supplements can help treat nonalcoholic fatty liver disease (NAFLD) by improving hepatic steatosis and lowering circulating triglycerides.[1]

Exercise Interventions

Aerobic Exercise: Frequent moderate-intensity aerobic exercise, such swimming or brisk walking, improves insulin sensitivity and lowers visceral fat, which helps NAFLD patients lose liver fat.[16]

Resistance Training: Including strength training activities helps PCOS patients manage their weight, grow their muscle mass, and boost their basal metabolic rate. In women with PCOS, resistance exercise has been demonstrated to enhance body composition and insulin sensitivity.[8]

7.2 Pharmacological Therapies

For PCOS

Metformin: Metformin is an insulin sensitizer that increases peripheral insulin sensitivity while decreasing hepatic glucose synthesis. It is frequently used to treat PCOS patients' hyperandrogenism and irregular menstrual periods. According to studies, metformin helps PCOS-afflicted women's metabolic and reproductive outcomes.[22]

Anti-Androgens: Drugs like oral contraceptives and spironolactone help lessen the symptoms of acne and hirsutism. In addition to treating hyperandrogenism, anti-androgens also indirectly increase insulin sensitivity.[24]

For NAFLD

GLP-1 Agonists for Receptors: These drugs, like liraglutide, have demonstrated potential in lowering hepatic fat and enhancing insulin sensitivity. They also help people lose weight, which is important for managing NAFLD.[23]

Vitamin E: This antioxidant has been shown to be effective in lowering oxidative stress and inflammation in the liver, which improves liver histology in non-diabetic patients with non-alcoholic steatohepatitis (NASH).[25]

For Insulin resistance

Metformin: Metformin is the first-line treatment for insulin resistance, particularly in conditions like PCOS and Type 2 diabetes. It works by reducing hepatic glucose production and improving peripheral insulin sensitivity. However, it may cause gastrointestinal side effects, and in rare cases, lactic acidosis.[22]

Thiazolidinediones: Thiazolidinediones (TZDs), such as pioglitazone, act by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which increases insulin sensitivity, especially in adipose tissue. While effective, they can cause weight gain, fluid retention, and increase the risk of heart failure.[8]

SGLT-2 inhibitors: such as empagliflozin, work by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion. These are primarily used in Type 2 diabetes but are also considered for PCOS-related

insulin resistance, with side effects like urinary tract infections, dehydration, and a risk of ketoacidosis.[16]

7.3 Emerging Therapies

Gut-Targeted Probiotics: Research has indicated that probiotic supplements that promote the restoration of gut microbial balance may enhance insulin sensitivity and lower systemic inflammation. The formation of advantageous metabolites such as short-chain fatty acids (SCFAs), which promote glucose metabolism and liver function, is influenced by probiotics.[14]

Epigenetic Modulation: New treatments that target epigenetic pathways seek to change the expression of genes associated with hepatic steatosis and insulin resistance. This includes studies on histone modification agents and DNA methylation inhibitors, which have shown promise in preclinical research.[16]

7.4 Integrated Multidisciplinary Approaches

Holistic Approaches: Endocrinology, hepatology, and lifestyle medicine must be used in conjunction to treat PCOS, IR, and NAFLD. Multidisciplinary teams can improve outcomes for many interrelated illnesses by customizing interventions based on each patient's unique metabolic profile.[21]

Patient-Centered Care: interdisciplinary cooperation guarantees all-encompassing treatment that incorporates medication management, lifestyle changes, and surveillance for related comorbidities such as heart disease and type 2 diabetes.[1]

8. Current Challenges and Research Directions

8.1 Barriers to Integrated Care

Lack of Unified Diagnostic Criteria: Inconsistencies in diagnosis and treatment arise when illnesses such as PCOS and NAFLD lack commonly accepted diagnostic standards. Although there are ongoing discussions on the Rotterdam criteria's clinical usefulness to a variety of groups, they are widely employed for PCOS. Similarly, non-invasive NAFLD diagnostic methods including imaging and blood biomarkers are not sensitive enough or specific enough, which results in early underdiagnosis.[25]

Fragmented Treatment Approaches: Different specializations treat the symptoms of certain illnesses separately, leading to a segmented approach to care. Rarely do gynecologists, hepatologists, and endocrinologists work together, which leads to less than ideal patient outcomes. Patients have a harder time navigating the healthcare system as a result of this fragmentation, which also makes integrated care more difficult.[21]

8.2 Research Gaps

Limited Longitudinal Data: The majority of research on the relationship between PCOS, IR, and NAFLD is cross-sectional, offering little information on how the illness develops over time. Longitudinal studies are required to investigate the progression of metabolic dysfunction and the effects of therapies on long-term results. For instance, knowing how women with PCOS move from hepatic steatosis to severe fibrosis should help guide focused therapies.[1]

Combined Intervention Trials: There is a dearth of research on treatments that treat PCOS, IR, and NAFLD all at once. Although lifestyle changes are frequently advised, not enough research has been done on how well they work to manage the three illnesses. Research examining pharmaceutical and lifestyle therapies in combination may yield important information about synergistic effects.[22]

8.3 Future Opportunities

AI-Powered Customized Therapy Routines: By examining intricate datasets, machine learning and artificial intelligence (AI) have the potential to improve diagnosis and therapy. To forecast personal risks and customize interventions, these technologies can combine genetic, metabolic, and clinical data. Additionally, AI-based technologies may improve screening procedures and allow for the early identification of NAFLD in high-risk PCOS populations.[5]

Investigation of Molecular Targets: Studies into particular molecular processes, such lipid metabolism and insulin signaling, may provide novel therapeutic targets. A novel approach to intervention is epigenetic therapy, which alters gene expression patterns linked to metabolic disorders.[16]

Data Particular to Sex and Ethnicity: Little is known about the ways in which sex and ethnicity affect the onset and course of PCOS and NAFLD. Customized studies could increase the precision of diagnoses and the effectiveness of treatments for a range of populations.[18]

CONCLUSION

PCOS, insulin resistance (IR), and non-alcoholic fatty liver disease (NAFLD) are interrelated disorders that require a comprehensive and collaborative strategy that incorporates clinical, molecular, and pharmacological insights. Common mechanisms like hormone dysregulation, chronic inflammation, and dyslipidemia highlight the necessity of coordinated approaches that target these underlying pathways at the same time.

In order to find new biomarkers, improve diagnostic instruments, and create focused interventions, interdisciplinary research initiatives are essential. For example, a better knowledge of the involvement of adipokines and epigenetics may result in improved hormonal therapy for PCOS and new therapeutic approaches for treating IR and liver fibrosis in NAFLD. Future research should focus on incorporating cutting-edge technologies such as molecular studies to investigate novel targets and artificial intelligence for

individualized therapy regimens. In order to improve results, this multifaceted strategy is essential.

REFERENCES

1. Vasilatou, E. (2014). Nonalcoholic fatty liver disease and polycystic ovary syndrome. World Journal of Gastroenterology: WJG, 20(26): 8351–8363. https://doi.org/10.3748/wjg.v20.i26.8351
2. Hong, S.-H., Sung, Y.-A., Hong, Y. S., Song, D. K., Jung, H., Jeong, K., Chung, H., & Lee, H. (2023). Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome. Scientific Reports, 13(1): 13397. https://doi.org/10.1038/s41598-023-39428-4
3. Asfari, M. M., Sarmini, M. T., Baidoun, F., Al-Khadra, Y., Ezzaizi, Y., Dasarathy, S., & McCullough, A. (2020). Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterology, 7(1): e000352. https://doi.org/10.1136/bmjgast-2019-000352
4. Won, Y. B., Seo, S. K., Yun, B. H., Cho, S., Choi, Y. S., & Lee, B. S. (2021). Non-alcoholic fatty liver disease in polycystic ovary syndrome women. Scientific Reports, 11(1): 7085. https://doi.org/10.1038/s41598-021-86697-y
5. Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023). Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research, 16(1): 9. https://doi.org/10.1186/s13048-022-01091-0
6. Dumitrașcu, D. L., & Neuman, M. G. (2018). Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Medical, 1957; 91(2): 147–150. https://doi.org/10.15386/cjmed-993
7. Kelley, C. E., Brown, A. J., Diehl, A. M., & Setji, T. L. (2014). Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World Journal of Gastroenterology: WJG, 20(39): 14172–14184. https://doi.org/10.3748/wjg.v20.i39.14172
8. Md Muslim, M. Z., Mohammed Jelani, A., Shafii, N., Yaacob, N. M., Che Soh, N. A. A., & Ibrahim, H. A. (2024). Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis. Journal of Ovarian Research, 17(1): 106. https://doi.org/10.1186/s13048-024-01436-x
9. Christ, J. P., & Cedars, M. I. (2023). Current guidelines for diagnosing PCOS. Diagnostics (Basel, Switzerland): 13(6). https://doi.org/10.3390/diagnostics13061113
10. Bani Mohammad, M., & Majdi Seghinsara, A. (2017). Polycystic ovary syndrome (PCOS): diagnostic criteria, and AMH. Asian Pacific Journal of Cancer Prevention: APJCP, 18(1): 17–21. https://doi.org/10.22034/APJCP.2017.18.1.17
11. Gutch, M., Kumar, S., Razi, S. M., Gupta, K. K., & Gupta, A. (2015). Assessment of insulin sensitivity/resistance. Indian Journal of Endocrinology and Metabolism, 19(1): 160–164. https://doi.org/10.4103/2230-8210.146874
12. Gayoso-Diz, P., Otero-González, A., Rodriguez-Alvarez, M. X., Gude, F., García, F., De Francisco, A., & Quintela, A. G. (2013). Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPRICE cross-sectional study. BMC Endocrine Disorders, 13(1): 47. https://doi.org/10.1186/1472-6823-13-47
13. Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010). Pathogenesis of non-alcoholic fatty liver disease. *QJM: Monthly Journal of the Association of Physicians*, *103*(2): 71–83. https://doi.org/10.1093/qjmed/hcp158
14. Guo, X., Yin, X., Liu, Z., & Wang, J. (2022). Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. *International Journal of Molecular Sciences*, *23*(24): 15489. https://doi.org/10.3390/ijms232415489
15. Caturano, A., Acierno, C., Nevola, R., Pafundi, P. C., Galiero, R., Rinaldi, L., Salvatore, T., Adinolfi, L. E., & Sasso, F. C. (2021). Non-Alcoholic Fatty Liver Disease: From pathogenesis to clinical impact. *Processes (Basel, Switzerland):* *9*(1): 135. https://doi.org/10.3390/pr9010135
16. Grander, C., Grabherr, F., & Tilg, H. (2023). Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. *Cardiovascular Research*, *119*(9): 1787–1798. https://doi.org/10.1093/cvr/cvad095
17. Ranathunga, I., Athukorala, T. G., Sumanatilleke, M., & Somasundaram, N. P. (2022). Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo. In *Research Square*. https://doi.org/10.21203/rs.3.rs-1937622/v1
18. Liu, J., Wu, Q., Hao, Y., Jiao, M., Wang, X., Jiang, S., & Han, L. (2021). Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. *Human Reproduction (Oxford, England)*, *36*(4): 1108–1119. https://doi.org/10.1093/humrep/deaa371
19. Bharali, M. D., Rajendran, R., Goswami, J., Singal, K., & Rajendran, V. (2022). Prevalence of polycystic ovarian syndrome in India: A systematic review and meta-analysis. *Cureus*, *14*(12): e32351. https://doi.org/10.7759/cureus.32351
20. Conlon, B. A., Beasley, J., M., Aebersold, K., Jhangiani, S. S., & Wylie-Rosett, J. (2013). Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). *Nutrients*, *5*(10): 4093–4114. https://doi.org/10.3390/nu5104093
21. Schwenger, K. J. P., & Allard, J. P. (2014). Clinical approaches to non-alcoholic fatty liver disease. *World Journal of Gastroenterology: WJG*, *20*(7): 1712–1723. https://doi.org/10.3748/wjg.v20.i7.1712
22. Marshall, J. C., & Dunaif, A. (2012). Should all women with PCOS be treated for insulin resistance?

Fertility and Sterility, *97*(1): 18–22. https://doi.org/10.1016/j.fertnstert.2011.11.036

23. Somagutta, M. R., Jain, M Uday, U., Pendyala, S. K., Mahadevaiah, A., Mahmutaj, G., Jarapala, N., Gad, M. A., Srinivas, P. M., Sasidharan, N., & Mustafa, N. (2022). Novel antidiabetic medications in polycystic ovary syndrome. *Discoveries (Craiova, Romania):* *10*(1): e145. https://doi.org/10.15190/d.2022.4
24. Moghetti, P., Tosi, F., Castello, R., Magnani, C. M., Negri, C., Brun, E., Furlani, L., Caputo, M., & Muggeo, M. (1996). The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. *The Journal of Clinical Endocrinology and Metabolism*, *81*(3): 952–960. https://doi.org/10.1210/jcem.81.3.8772557
25. Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S., & Bolondi, L. (2018). Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. *World Journal of Gastroenterology: WJG*, *24*(30): 3361–3373. https://doi.org/10.3748/wjg.v24.i30.3361
26. Dyson, J. K., Anstee, Q. M., & McPherson, S. (2015). Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. *Postgraduate Medical Journal*, *91*(1072): 92–101. https://doi.org/10.1136/postgradmedj-2013-100404rep
27. Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021). Role of Insulin Resistance in MAFLD. *International Journal of Molecular Sciences*, 22. https://doi.org/10.3390/ijms22084156.